138 related articles for article (PubMed ID: 10174474)
1. Cost and utilisation of pharmaceuticals in Sweden.
Ljungkvist MO; Andersson D; Gunnarsson B
Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
[TBL] [Abstract][Full Text] [Related]
2. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
Burstall ML
Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical expenditure in Sweden.
Henriksson F; Hjortsberg C; Rehnberg C
Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
[TBL] [Abstract][Full Text] [Related]
4. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
Andersson K; Bergström G; Petzold MG; Carlsten A
Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
[TBL] [Abstract][Full Text] [Related]
5. Management of cost and utilization of pharmaceuticals in Germany.
von der Schulenburg JM
Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
[TBL] [Abstract][Full Text] [Related]
6. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
7. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
Bergman MA; Granlund D; Rudholm N
Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical cost containment and innovation in the United States.
Kane NM
Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
[TBL] [Abstract][Full Text] [Related]
9. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
10. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
[TBL] [Abstract][Full Text] [Related]
11. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
Persson U; Svensson J; Pettersson B
Appl Health Econ Health Policy; 2012 Jul; 10(4):217-25. PubMed ID: 22676213
[TBL] [Abstract][Full Text] [Related]
12. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
13. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
Gross DJ; Ratner J; Perez J; Glavin SL
Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
[TBL] [Abstract][Full Text] [Related]
14. Comparative experience in home care and pharmaceutical policy.
Kane NM; Saltman RB
Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467
[No Abstract] [Full Text] [Related]
15. Projecting future drug expenditures--1998.
Mehl B; Santell JP
Am J Health Syst Pharm; 1998 Jan; 55(2):127-36. PubMed ID: 9465976
[TBL] [Abstract][Full Text] [Related]
16. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
Freemantle N
Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
[TBL] [Abstract][Full Text] [Related]
17. Healthcare reform and expenditure on drugs. The German situation.
Ulrich V; Wille E
Pharmacoeconomics; 1996; 10 Suppl 2():81-8. PubMed ID: 10163440
[TBL] [Abstract][Full Text] [Related]
18. Pricing and reimbursement of pharmaceuticals in Sweden.
Jönsson B
Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond the drug budget silo mentality in Europe.
Drummond M; Jönsson B
Value Health; 2003; 6 Suppl 1():S74-7. PubMed ID: 12846928
[No Abstract] [Full Text] [Related]
20. Pharmaceuticals in U.S. health care: determinants of quantity and price.
Berndt ER
J Econ Perspect; 2002; 16(4):45-66. PubMed ID: 15179978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
